Compare Five9 Inc (FIVN) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs Medpace Holdings Inc — how do they compare? Five9 Inc trades at $36.4 (market cap $2.63B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 6.4× Five9 Inc's market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 1,864,393). Which is the better fit depends on your goals — on Pluang, investors hold Five9 Inc for 72 Days and Medpace Holdings Inc for 14 Days on average.
| FIVN | MEDP | |
|---|---|---|
Market Cap | $2.63B | $16.82B |
Volume | 1,864,393 | 223,093 |
Sector | Technology | Health |
52-Week High | $38.65 | $630.19 |
52-Week Low | $13.61 | $393.42 |
Typical Hold Time | 72 Days | 14 Days |
Enterprise Value | $2.78B | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) is trading at $35.15, up 4.06% with strong technical momentum and bullish moving average signals. The company shows accelerating revenue growth, reaching $1.15B in 2025 with improving profitability as net income turned positive at $39.42M. Recent quarterly earnings consistently beat expectations, while AI revenue surged 78% YoY to $39M in Q2 2026. The stock trades near resistance at $35 with solid institutional support despite recent insider selling activity.
FIVN presents growth potential driven by AI contact center adoption and subscription revenue expansion, but faces valuation concerns with a 51.69 P/E ratio. Key risks include competitive pressure in CCaaS markets and execution challenges in maintaining current growth trajectory. Analyst consensus remains bullish with 61% buy ratings and $34 price target, though current price exceeds consensus target.
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
